Coherus BioSciences Inc (CHRS)vsVertex Pharmaceuticals Inc (VRTX)
CHRS
Coherus BioSciences Inc
$1.45
-7.94%
HEALTHCARE · Cap: $227.52M
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 25961% more annual revenue ($12.22B vs $46.88M). CHRS leads profitability with a 397.3% profit margin vs 35.5%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CHRS
Hold47
out of 100
Grade: D+
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CHRS.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 397 of every $100 in revenue as profit
Revenue surging 62.0% year-over-year
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
ROE of -192.9% — below average capital efficiency
Earnings declined 75.5%
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CHRS
The strongest argument for CHRS centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 397.3% and operating margin at -293.7%. Revenue growth of 62.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CHRS
The primary concerns for CHRS are Market Cap, Return on Equity, EPS Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CHRS profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
CHRS carries more volatility with a beta of 0.96 — expect wider price swings.
CHRS is growing revenue faster at 62.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 47/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coherus BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?